Treating patients with a drug called aprotinin reduces the risk of stroke by 47 percent in patients undergoing coronary artery bypass graft (CABG) surgery, according to a study published in the Journal of Thoracic and Cardiovascular Surgery.
The study, a large-scale analysis evaluating data from 35 CABG studies, determined that use of aprotinin reduced the need for a blood transfusion by 39 percent. Blood transfusions during CABG surgery have been associated with an increased risk of stroke. Stroke and neurological injury occurs in five percent of the more than 300,000 CABG surgeries performed annually. "Our results highlight that aprotinin therapy might be recommended in all primary CABG surgeries after applicability to individual centers and patients is considered," said lead investigator Artyom Sedrakyan, M.D., researcher at Yale School of Medicine and lecturer at London School of Hygiene and Tropical Medicine. "About 10 strokes could be avoided in every 1,000 CABG patients with the use of aprotinin, which is a substantial stroke reduction benefit."
The study also showed that aprotinin therapy was associated with a trend toward reduced atrial fibrillation and did not increase the risk of adverse events including mortality, myocardial infarction and renal failure. "The cerebroprotective and anti-inflammatory effects of aprotinin therapy in CABG surgery, associated with improved neurological outcomes, have been reported in previous studies," said Sedrakyan, who did his work in the cardiothoracic department at Yale. "Our study further indicates that the balance of effects is positive with aprotinin use. Future studies should address the cost-effectiveness of this medication as it is substantially more costly in America as compared to the United Kingdom or the rest of Europe."
Karen N. Peart | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences